Mode
Text Size
Log in / Sign up
N/A N=38 Randomized Double-blind Basic Science

Alcohol and Neural Cardiovascular Control in Binge Drinkers

Binge Drinking

Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Sympathetic Nerve Activity Burst Frequency — 18; 20 Burst/Min — p=0.283

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Alcohol vs. Placebo (Other)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Baylor University
Primary completion
Jul 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Sympathetic Nerve Activity Burst Frequency
18; 20 0.283
PRIMARY
Sympathetic Nerve Activity Burst Incidence
31; 31
SECONDARY
Spontaneous Sympathetic Baroreflex Sensitivity
-2; -2 0.888

Summary

This study evaluates the impact of evening alcohol consumption on sympathetic activity and baroreflex function in binge drinkers. Our central hypothesis is that evening binge alcohol consumption will lead to sympathetic overactivity and blunted baroreflex function.

Eligibility Criteria

Inclusion Criteria

  • Men and women age 21 - 40 years
  • Binge drinkers as defined by a pattern of consuming ≥4 drinks if female (≥5 drinks if males) in ≤ 2 hours on more than one occasion within the past 6 months, and at least once in the past 30 days. The National Institute of Alcohol Abuse and Alcoholism (NIAAA) definition of a "drink" will be used.
  • Women must be eumenorrheic and premenopausal with regular and consistent menstrual cycles (i.e., ~25-30 days ovarian/uterine cycles that include 2-7 days of menstruation)
  • Willingness to abstain from exercise and caffeine at least 12 hours prior to any autonomic and cardiovascular testing, and abstain from alcohol 24 hours prior to any autonomic and cardiovascular testing (unless experimentally administered).

Exclusion Criteria

  • Body mass index ≥ 35 kg/m2
  • Smokers
  • A physician diagnosis of diabetes
  • Pregnancy
  • Taking any cardiovascular medications
  • Severe obstructive sleep apnea as determined by an apnea-hypopnea index of ≥ 30 episodes per hour
  • Moderate-to-severe Alcohol Use Disorder (AUD) as determined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
  • Individuals suspected to have mutant alcohol dehydrogenase 2 (ALDH2) isoenzyme as determined using a validated flushing questionnaire
  • Women using hormonal contraceptives (i.e., oral, intrauterine, etc.) in the prior 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03567434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search